PT - JOURNAL ARTICLE AU - ANTONIO ROSSI AU - GIUSEPPE COLANTUONI AU - NICOLA CANTORE AU - LUIGI PANICO AU - GIOVANNI DE CHIARA AU - UMBERTO FERBO AU - CESARE GRIDELLI TI - Complete Response of Severe Symptomatic Bone Marrow Metastases from Heavily Pretreated Breast Cancer with a 3-Weekly Trastuzumab Schedule. A Clinical Case DP - 2004 Jan 01 TA - Anticancer Research PG - 317--320 VI - 24 IP - 1 4099 - http://ar.iiarjournals.org/content/24/1/317.short 4100 - http://ar.iiarjournals.org/content/24/1/317.full SO - Anticancer Res2004 Jan 01; 24 AB - Overexpression of HER-2/neu in breast cancer has been associated with more aggressive disease and poor overall survival. Trastuzumab, a recombinant humanized monoclonal antibody with high affinity for the HER-2 protein, inhibits the growth of breast cancer cells overexpressing HER-2. Trastuzumab showed, as second-line treatment, 15% of objective response in metastatic breast cancer. Bone marrow metastases are detectable in 23% of the patients with advanced breast cancer at first relapse and this rate increases in patients with metastatic disease. We report a case of a complete response of bone marrow metastases from breast cancer using a 3-weekly trastuzumab schedule, in a heavily pretreated patient with severe symptomatic pancitopenia.